Cocrystal Pharma, Inc. (COCP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the COCP SEC filings page.
This page shows Cocrystal Pharma, Inc. (COCP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cocrystal remains a development-stage business, with lower spending reducing losses while operations still consume cash and financing supports the balance sheet.
Earnings quality is relatively consistent: the 2025 net loss was$8.8M and operating cash outflow was$8.2M , closely matching the same relationship in FY2024. That narrow gap means reported losses largely reflect ongoing cash costs rather than a large non-cash accounting adjustment.
The improvement in FY2025 came alongside R&D falling to
Financing remains important: FY2025 included
Financial Health Signals
Cocrystal Pharma, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cocrystal Pharma, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Cocrystal Pharma, Inc. reported a net loss of $8.8M while operations used $8.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cocrystal Pharma, Inc. reported an operating loss of $9.0M against $134K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cocrystal Pharma, Inc. generated $105K in revenue in Q2 2026. Against the prior quarter it is down 53.3%.
Cocrystal Pharma, Inc.'s EBITDA was -$3.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 52.0% from the same quarter a year earlier. Against the prior quarter it is down 35.3%.
Cocrystal Pharma, Inc. reported -$3.2M in net income in Q2 2026. This represents a decrease of 54.0% from the same quarter a year earlier. Against the prior quarter it is down 37.6%.
Cocrystal Pharma, Inc. earned -$0.23 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 35.3%.
Cash & Balance Sheet
Cocrystal Pharma, Inc. held $2.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Cocrystal Pharma, Inc.'s ROE was -303.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 264.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 247.2 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Cocrystal Pharma, Inc. invested $2.1M in research and development in Q2 2026. This represents an increase of 90.9% from the same quarter a year earlier. Against the prior quarter it is up 56.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
COCP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $105K | $225K | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.1M+90.9% | $1.4M+0.8% | N/A | $954K-70.6% | $1.1M-74.0% | $1.4M-53.9% | N/A | $3.2M-22.7% |
| SG&A Expenses | $1.1M+16.3% | $1.2M+23.3% | N/A | $1.1M-36.9% | $986K-13.5% | $981K-18.8% | N/A | $1.8M-2.7% |
| Operating Income | -$3.2M-51.0% | -$2.4M-0.6% | N/A | -$2.1M+58.6% | -$2.1M+61.3% | -$2.3M+43.7% | N/A | -$5.0M-13.5% |
| EBITDA | -$3.2M-52.0% | -$2.3M-1.2% | N/A | -$2.1M+58.6% | -$2.1M+61.5% | -$2.3M+43.8% | N/A | -$5.0M-14.2% |
| Interest Expense | -$10K+64.3% | -$22K+40.5% | N/A | -$22K+80.2% | -$28K+81.5% | -$37K+83.2% | N/A | -$111K+65.3% |
| Income Tax | N/A | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.2M-54.0% | -$2.3M+0.1% | N/A | -$2.0M+58.5% | -$2.1M+61.5% | -$2.3M+41.8% | N/A | -$4.9M-18.6% |
| EPS (Basic) | -$0.23-15.0% | -$0.17+26.1% | -$0.17+46.9% | -$0.19+61.2% | -$0.20+62.3% | -$0.23+41.0% | -$0.32+27.3% | -$0.49-19.5% |
| EPS (Diluted) | -$0.23 | -$0.17+26.1% | -$0.17+46.9% | -$0.19+61.2% | -$0.20+62.3% | -$0.23+41.0% | -$0.32+27.3% | -$0.49-19.5% |
| Diluted Shares (Avg) | 14M | 14M+35.5% | N/A | 11M+8.0% | 10M0.0% | 10M0.0% | N/A | 10M+0.2% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
COCP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.6M-45.3% | $7.4M-30.3% | $9.7M-27.8% | $10.4M-35.6% | $8.5M-60.6% | $10.7M-59.8% | $13.5M-57.0% | $16.2M-50.2% |
| Current Assets | $3.2M-52.2% | $5.9M-32.7% | $8.1M-29.8% | $8.8M-38.4% | $6.8M-65.6% | $8.8M-64.0% | $11.6M-60.2% | $14.3M-55.7% |
| Cash & Equivalents | $2.2M-54.5% | $4.7M-32.3% | $7.0M-28.8% | $7.7M-41.0% | $4.8M-73.7% | $6.9M-68.3% | $9.9M-62.6% | $13.1M-56.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.6M+13.7% | $3.3M-1.3% | $3.4M-14.0% | $2.8M-21.3% | $3.2M-24.2% | $3.4M-15.3% | $3.9M-19.3% | $3.5M+83.5% |
| Current Liabilities | $2.6M+42.9% | $2.2M+15.4% | $2.2M-9.0% | $1.5M-22.0% | $1.8M-31.0% | $1.9M-18.8% | $2.4M-25.6% | $1.9M+1.2% |
| Non-Current Liabilities | $989K-26.2% | $1.1M-24.1% | $1.2M-22.2% | $1.3M-20.5% | $1.3M-12.3% | $1.4M-10.0% | $1.5M-6.7% | $1.6M |
| Total Equity | $1.0M-80.4% | $4.1M-43.6% | $6.3M-33.5% | $7.7M-39.6% | $5.3M-69.3% | $7.3M-67.7% | $9.5M-63.9% | $12.7M-58.6% |
| Retained Earnings | -$347.7M-2.9% | -$344.5M-2.6% | -$342.2M-2.6% | -$339.8M-2.9% | -$337.8M-3.9% | -$335.7M-5.0% | -$333.4M-5.5% | -$330.2M-6.0% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
COCP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.5M-16.8% | -$2.3M+20.4% | -$1.7M+45.1% | -$1.4M+73.4% | -$2.2M+41.7% | -$2.9M+34.7% | -$3.2M+5.0% | -$5.1M-91.1% |
| Depreciation & Amortization | $12K-42.9% | $12K-52.0% | $13K-53.6% | $13K-56.7% | $21K-36.4% | $25K-28.6% | $28K-30.0% | $30K-43.4% |
| Stock-Based Compensation | N/A | $84K+2.4% | N/A | $48K-81.0% | $84K-49.4% | $82K-47.8% | N/A | $252K-54.8% |
| Capital Expenditures | N/A | N/A | $0 | N/A | N/A | N/A | $0-100.0% | $0 |
| Free Cash Flow | N/A | N/A | -$1.7M+45.1% | N/A | N/A | N/A | -$3.2M+6.6% | -$5.1M-91.1% |
| Investing Cash Flow | N/A | N/A | $0 | N/A | N/A | N/A | $0+100.0% | $0 |
| Financing Cash Flow | N/A | N/A | $1.0M | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
COCP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3032.4% | -1047.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -3013.3% | -1021.8% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -303.1%-264.5pp | -55.9%-24.4pp | N/A | -26.7%+12.2pp | -38.5%-7.8pp | -31.5%-14.0pp | N/A | -38.9%-25.3pp |
| Return on Assets | -68.1%-43.9pp | -31.0%-9.4pp | N/A | -19.6%+10.8pp | -24.2%+0.6pp | -21.6%-6.7pp | N/A | -30.4%-17.7pp |
| Current Ratio | 1.24-2.5x | 2.66-1.9x | 3.68-1.1x | 5.78-1.5x | 3.69-3.7x | 4.57-5.7x | 4.77-4.1x | 7.32-9.4x |
| Debt-to-Equity | 3.45+2.9x | 0.80+0.3x | 0.53+0.1x | 0.36+0.1x | 0.59+0.4x | 0.46+0.3x | 0.41+0.2x | 0.28+0.2x |
| Asset Turnover | 0.02 | 0.03 | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cocrystal Pharma, Inc. COCP | FY2025 | N/A | -$8.8M | N/A | $19.8M | — |
| Imunon, Inc. IMNN | FY2025 | N/A | $14.5M | N/A | $5.8M | — |
| Portage Biotech Inc. PRTG | FY2018 | N/A | $123.7M | N/A | $15.5M | — |
| Athira Pharma, Inc. ATHA | FY2025 | N/A | -$106.0M | N/A | $26.6M | — |
| Cyclacel Pharmaceuticals, Inc CYCC | FY2025 | $747K | $3.0M | N/A | $15.2M | — |
| BioVie, Inc. BIVI | FY2026 | N/A | -$22.1M | N/A | $10.1M | — |
Where Cocrystal Pharma, Inc. Ranks
Frequently Asked Questions
Is Cocrystal Pharma, Inc. profitable?
No, Cocrystal Pharma, Inc. (COCP) reported a net income of -$8.8M in fiscal year 2025.
What is Cocrystal Pharma, Inc.'s EBITDA?
Cocrystal Pharma, Inc. (COCP) had EBITDA of -$8.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cocrystal Pharma, Inc.'s return on equity (ROE)?
Cocrystal Pharma, Inc. (COCP) has a return on equity of -139.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cocrystal Pharma, Inc.'s free cash flow?
Cocrystal Pharma, Inc. (COCP) recorded an outflow of $8.2M in free cash flow during fiscal year 2025. This represents a 50.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cocrystal Pharma, Inc.'s operating cash flow?
Cocrystal Pharma, Inc. (COCP) recorded an outflow of $8.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cocrystal Pharma, Inc.'s total assets?
Cocrystal Pharma, Inc. (COCP) had $9.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cocrystal Pharma, Inc.'s capital expenditures?
Cocrystal Pharma, Inc. (COCP) invested $12K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cocrystal Pharma, Inc. spend on research and development?
Cocrystal Pharma, Inc. (COCP) invested $5.1M in research and development during fiscal year 2025.
What is Cocrystal Pharma, Inc.'s current ratio?
Cocrystal Pharma, Inc. (COCP) had a current ratio of 3.68 as of fiscal year 2025, which is generally considered healthy.
What is Cocrystal Pharma, Inc.'s debt-to-equity ratio?
Cocrystal Pharma, Inc. (COCP) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cocrystal Pharma, Inc.'s return on assets (ROA)?
Cocrystal Pharma, Inc. (COCP) had a return on assets of -90.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cocrystal Pharma, Inc.'s P/E ratio?
Cocrystal Pharma, Inc. (COCP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $19.8M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cocrystal Pharma, Inc.'s price-to-sales ratio?
Cocrystal Pharma, Inc. (COCP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $19.8M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Cocrystal Pharma, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cocrystal Pharma, Inc. (COCP) held $7.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.2M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Cocrystal Pharma, Inc.'s Piotroski F-Score?
Cocrystal Pharma, Inc. (COCP) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cocrystal Pharma, Inc.'s earnings high quality?
Cocrystal Pharma, Inc. (COCP) reported a net loss of $8.8M while operations used $8.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cocrystal Pharma, Inc. cover its interest payments?
Cocrystal Pharma, Inc. (COCP) reported an operating loss of $9.0M against $134K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.